EF Hutton analyst Chip Moore maintains Hudson Technologies (NASDAQ:HDSN) with a Buy and raises the price target from $11 to $12.
Aurinia Presents Breadth Of Data From AURORA Clinical Program Underscoring Value Of LUPKYNI For Patients With Lupus Nephritis At ACR 2023
A propensity analysis of AURORA 1 suggested that initial therapy with LUPKYNIS® plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen
